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Abstract: An early detection tool for latent COVID-19 infections in oncology staff and patients is essential
to prevent outbreaks in a cancer center. (1) Background: In this study, we developed and implemented
two early detection tools for the radiotherapy area to identify COVID-19 cases opportunely. (2) Methods:
Staff and patients answered a questionnaire (electronic and paper surveys, respectively) with clinical
and epidemiological information. The data were collected through two online survey tools: Real-Time
Tracking (R-Track) and Summary of Factors (S-Facts). Cut-off values were established according to the
algorithm models. SARS-CoV-2 qRT-PCR tests confirmed the positive algorithms individuals. (3) Results:
Oncology staff members (n = 142) were tested, and 14% (n = 20) were positives for the R-Track algorithm;
75% (n = 15) were qRT-PCR positive. The S-Facts Algorithm identified 7.75% (n = 11) positive oncology
staff members, and 81.82% (n = 9) were qRT-PCR positive. Oncology patients (n = 369) were evaluated,
and 1.36% (n = 5) were positive for the Algorithm used. The five patients (100%) were confirmed by
qRT-PCR. (4) Conclusions: The proposed early detection tools have proved to be a low-cost and efficient
tool in a country where qRT-PCR tests and vaccines are insufficient for the population.
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1. Introduction

iations.

The outbreak of the coronavirus disease 2019 (COVID-19) was declared a pandemic
on 11 March 2020 by the World Health Organization (WHO) [1]. The new coronavirus
(SARS-CoV-2) can infect people of all ages. However, older people and individuals with
pre-existing medical conditions (such as cancer, asthma, diabetes, obesity, hypertension,
and heart disease) appear more vulnerable to becoming seriously ill. COVID-19 has a
mortality rate >8% in people older than 70 years [2,3].
Oncologic patients are at higher risk of severe COVID-19 infection and worse prognosis
than non-cancer patients [2]. Some systematic reviews concluded an increased risk of severe
COVID-19 in oncologic patients due to associated co-morbidities linked to cancer [4].
The clinical diagnosis of COVID-19 is based mainly on epidemiological history and
clinical manifestations. However, the clinical symptoms and signs of patients infected
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with SARS-CoV-2 are highly variable. Therefore, additional tests for detecting the virus
are needed, such as qRT-PCR [5]. Many people have flu-like symptoms onset; However,
widespread population testing is not available in developing countries. Thus, it is essential
to develop an early detection tool to evaluate symptoms with the most predictive value
to identify COVID-19 without molecular testing. The early detection tool implementation
is an effort to guide public health recommendations for self-detection, self-isolation, early
detection, and preventing the further spread of the disease.
Digital health and information technologies have emerged to support public health
policies and offer opportunities to reshape current health care systems, especially in developed countries [6,7]. They are used for early detection, prevention, and advice for
skeletal injuries, chronic orthopedic conditions, smoking, cancer, diabetes, and infectious
diseases [8–11]. Furthermore, digital health and information technologies are helpful for
the widespread distribution of information, real-time COVID-19 transmission tracking,
virtual venue creation, and telemedicine visits for patients [12–18]. Digital health and
information technologies are helpful in infectious diseases such as HIV, bacterial resistance,
and hospital sepsis.
In Mexico, qRT-PCR tests are not available for the entire population. Since the virus
began spreading in the country, nearly 2500 Mexican health workers have died from
COVID-19, and 188,000 have been infected as of 4 January 2021. Mexico holds the highest
mortality rate in patients and medical staff worldwide [19]. Therefore, digital technologies’
early detection tools can be an excellent option for detecting and preventing COVID-19 in
our country.
As a cancer center in a developing country that works with high-risk patients, this
study aimed to develop and implement two early detection tools that used self-reported
COVID-19 symptoms for patients and oncology staff members (O.S.M.) for early diagnosis
at low cost. For validation of these two algorithms, we calculated the sensitivity for
each detection algorithm for COVID-19 positive cases confirming results by qRT-PCR and
immunological test. In addition to this, we implement personal protective equipment,
isolation measures, staff training, and sanitary fences for SARS-CoV-2.
2. Materials and Methods
2.1. Study Population
We used a total of 142 O.S.M. and 369 patients. We conducted a retrospective research
study in the Centro Universitario Contra el Cáncer (C.U.C.C.) of the Universidad Autónoma
de Nuevo León (U.A.N.L.) in Monterrey, Nuevo León, México. The work areas of the oncology
staff include medical oncology, radiotherapy (R.T.), nursing, molecular biology laboratory,
social work, C.U.C.C. Early Cancer Detection Clinic (C.E.C.I.L.), clinical protocols area, and
administration. Patients were visited in the Radiotherapy Unit of C.E.C.I.L. This study was
conducted following the Declaration of Helsinki. The Institutional Ethics Committee approved
the protocol of the University Hospital (ON21-00012). All employees and patients answered a
questionnaire with clinical and epidemiological information, and a confirmatory molecular
test was applied to those who presented suggestive COVID-19 symptoms.
2.2. O.S.M. Training and Personal Protection Equipment (P.P.E.)
All O.S.M. were trained to prevent and identify SARS-CoV-2 infection. A face-to-face
course was held, keeping a 6 ft. distance. Groups of 10 people received training from a
radio-oncologist, a nurse, and two PhDs. The course lasted one hour and aimed to educate
oncology staff to identify the most common symptoms for both cancer and non-cancer
patients and the period of appearance of symptoms. They also received training to answer
an electronic survey with two predictive models for the early detection of probable cases of
COVID-19; they were given the correct filling steps, the link, and the Q.R. code to answer
the survey. The sanitary fences (isolation) assigned to prevent the transmission of the
virus were identified; the importance of handwashing and the use of a face mask were
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explained. The steps for sanitizing areas and how to prepare the cleaning solutions were
also described.
Individual safety measures were implemented for all O.S.M., among which the use of
P.P.E. (face masks and face shields) was mandatory and provided by the Oncology Center.
COVID-19 symptomatic O.S.M. were treated at U.A.N.L. Employee Health Clinic, and
severe symptomatic O.S.M. were referred to the COVID-19 U.A.N.L. Hospital.
2.3. Application of Electronic Surveys to O.S.M.
The O.S.M. was given the “Survey for Personnel-Test Covid 19” from March 2020 to
January 2021, with a frequency of 2 electronic surveys per week. Two predictive algorithm
models were used: Real-Time Tracking (R-Track) and Summation of Factors (S-Facts). The
surveys were applied through mobile devices to monitor symptoms in the staff and detect
potential COVID-19 cases before entry to the work area. Employee’s positives for the algorithms were confirmed by qRT-PCR. In addition to the algorithm, epidemiological variables,
nonspecific (general) symptoms, co-morbidities, and risk factors were documented. We
also include questions to trace O.S.M.’s close contact with COVID-19 positive individuals,
such as family members or friends with symptoms or confirmed with COVID-19. No
person with fever or low oxygen saturation, including O.S.M. or patients, were admitted
to ingress to C.U.C.C. They were referred directly to the COVID-19 U.A.N.L. Hospital for
clinical evaluation and qRT-PCR tests.
2.3.1. R-Track Predictive Model
The R-Track survey was adjusted for age, sex, and symptoms (dysgeusia and/or
anosmia, persistent dry cough, severe fatigue, and meal skipping) to identify symptoms
correlated with COVID-19. The following formula was used to identify the probable
COVID-19 cases:
x = −1.32 (0.01 × Age) + (0.44 × Sex) + (1.75 × dysgeusia and/or anosmia) + (0.31 ×
Persis-tent dry cough) + (0.49 × Severe fatigue) + (0.39 × Meal skipping).
A value of 1 was assigned if the person self-reports the symptom and 0 if not. The sex
feature was also binary, with 1 indicative of male participants and 0 representing females.
The values were transformed into predictive probability using exp(x)/(1 + exp(x)). A
result calculation followed by assigning cases of predicted COVID-19 for probabilities ≥0.5
and controls for probabilities <0.5, according to the Menni y cols study [13].
2.3.2. S-Facts Predictive Model
In the S-Facts survey, the most common and specific symptoms of the disease were
evaluated. The formula used was the following:
Probability = (1.0 ×Dyspnea) + (1.0 × Temperature ≥ 38.0 ◦ C) + (1.0 × Chest pain) +
(1.0 × Dysgeusia and/or anosmia) + (1.0 × Persistent dry cough) + (1.0 × Severe fatigue) +
(1.0 × Meal skipping).
Results with values ≥3.0 were considered positive for SARS-CoV-2 risk infection [14].
2.4. Detection of SARS-CoV-2 IgM and IgG Antibodies in O.S.M.
A total of 140 O.S.M. were tested for COVID-19 antibodies in March 2021. We used
the qualitative membrane-based immunoassay Coronavirus (2019-nCoV) IgG/IgM Test
Kit (Genrui® Biotech Inc., Shenzhen, China) to detect IgM and IgG antibodies against
SARS-CoV-2 in whole blood according to the manufacturer’s instructions.
2.5. Paper Surveys for Radiotherapy Area Patients
A paper survey was applied to cancer patients treated at the radiotherapy area from
October 2020 to February 2021. Temperature and oxygen saturation were recorded before
patients attended at C.E.C.I.L. clinic. The survey studied the most significant symptoms
for COVID-19 (temperature ≥ 38 ◦ C, persistent dry cough, dyspnea, dysgeusia, and/or
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anosmia). Nonspecific symptoms such as headache, diarrhea, chest pain, runny nose,
arthralgia, myalgia, redness, and itching eyes, were also registered.
Radiotherapy patients had additional screening questions. Further questions included:
(1) If they had direct contact with a confirmed COVID-19 positive family member or
friend, (2) If they traveled outside the Monterrey metropolitan area in the last 15 days
(Supplementary Material 1: Table S1). A value ≥7 indicated a high probability of having
COVID-19 (positives for the algorithm). Patients were confirmed by qRT-PCR.
Additionally, we designed a unique brochure for oncology patients. All patients and
their caregivers who entered the C.U.C.C. for consultation, chemotherapy, radiotherapy,
or consultation received the pamphlet. The pamphlet emphasizes the importance of early
detection and prevention of COVID-19 infection in oncological patients. It also details the
clinical data presented in cancer patients and the high risk of developing severe symptoms
(Supplementary Material 2: Figure S1).
2.6. Sample Collection for SARS-CoV-2 qPCR Assay
The samples were collected following the CDC (Control Disease Center) guidelines [15]. The detailed information on packing, shipping, and transporting specimens can
be found at Interim Laboratory Biosafety Guidelines for Handling and Processing Specimens Associated with Coronavirus Disease 2019 (COVID-19) on the CDC website [15].
2.7. RNA Extraction
After nasopharyngeal sample collection, total RNA was isolated using the QIAamp®
RNA Viral Mini Kit from QIAGEN (Hilden, Germany) in the QIAcube connect system from
QIAGEN according to the manufacturer’s instructions. The RNA samples were stored at
−80 ◦ C until further use.
2.8. qRT-PCR Tests
We used qRT-PCR assay 2019-nCoV R.N.A. (2019-nCoV) Probe Assay from IDT (Integrated DNA Technologies Inc., Coralville, IA, USA). Two targets from one gene, the
nucleocapsid protein (2019-nCoV_N1 and 2019-nCoV_N2) and the human gene RNAase,
were simultaneously amplified during the real-time RT-PCR assay. These diagnostic conditions follow the CDC recommendations conditions.
3. Results
3.1. Electronic Surveys and Antibodies Detection in O.S.M.
O.S.M. were surveyed (n = 142, men n= 58 and women n = 84, median age 32 years
old, range of 18–67 years old). Two surveys a week yielded a total of 3327 surveys from
March 2020 to January 2021. We also studied the presence of the most relevant risk comorbidities for COVID-19 in O.S.M. and patients. We found that 26.8% of employees had
co-morbidities (n = 38, men n = 16, and women n = 22). Obesity was the more frequently
observed co-morbidity in men 50% (8/16) and women 36.4% (8/22). Hypertension in 22.7%
(5/22) and asthma in 18.2% (4/22) were among the most common (Figure 1).
3.1.1. R-Track and S-Facts Algorithm for O.S.M Screening
With the R-Track model, we identified 20 employees with suggestive clinical data of
COVID-19 infection, of which 75.0% (15/20) were qRT-PCR positive for SARS-CoV-2.
Using the S-Facts Algorithm, we identified 11 employees with suggestive symptoms
of COVID-19, of which 81.8% (9/11) were qRT-PCR positive. False-positive results were
obtained with both models. With the R-Track model, five employees presented alerts in
the algorithm. Still, they were qRT-PCR negative, and the S-Fact two employees with a
warning in the algorithm were qRT-PCR negative.
A total of 12% (17/142) of O.M.S. identified as positive with the algorithms were
SARS-CoV-2 qRT-PCR positive. The age range was 18 to 62 years, and 58.8% (10/17) were
female. Among positive O.S.M., obesity was observed in 23.5% (4/17). Administrative and
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nursing staff had the highest incidence of COVID-19 with 35.3% (6/17) per group (Table 1).
We found that 64.7% (11/17) of staff with SARS-CoV-2 qRT-PCR positive also documented
5 of 13
a high-risk exposure. Close contact with individuals with symptoms or previous
COVID-19
infection increased the probability of contracting the disease (Table 1).
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3.1.1. R-Track and S-Facts Algorithm for O.S.M Screening
Table 1. Epidemiological characteristics of 17 O.M.S./qRT-PCR positive for SARS-CoV-2 identified
With the R-Track model, we identified 20 employees with suggestive clinical data of
with the algorithms (n = 17).
COVID-19 infection, of which 75.0% (15/20) were qRT-PCR positive for SARS-CoV-2.
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were qRT-PCR negative, and the S-Fact two10employees
with a
Co- morbidities
warning in the algorithm
were
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A total of
12% (17/142)
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64.7% (11/17) of staff with SARS-CoV-2 qRT-PCR positive
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*
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Table 1. Epidemiological
characteristics
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We analyzed the main symptoms of the oncology staff with COVID-19. We found
that the most common symptoms were skipped meals with 76.5% (13/17) and dysgeusia/anosmia with 82.4% (14/17). Other symptoms included headaches with 70.6% (12/17),
muscle or body aches with 70.6% (12/17), runny nose with 58.8% (10/17), and sore throat
with 58.8% (10/17) (Table 1).
O.S.M. (n = 14) that self-identified suggestive symptoms of COVID-19 directly visited
the COVID-19 UANL hospital. All were confirmed the COVID-19 diagnosis with a positive
qRT-PCR test. In May 2020, the first oncology staff member was confirmed with COVID-19.
The month with the highest incidence of COVID-19 infection was December, where we
found seven new confirmed cases in total (cases identified with/without the algorithms).
7 of 13
In total, 21.8% (31/142) of O.S.M. were qRT-PCR SARS-CoV-2 positive (Figure 2).
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Of the 62 employees who raised antibodies against COVID-19, 62.9% (39/62) generated IgG-type memory antibodies), 28.2% (11/39) had antibodies against COVID-19 after
a previous infection, and a COVID-19 vaccine, 25.6% (15/39) had antibodies against
COVID-19 after a COVID-19 vaccine without previous infection. We observed that 8.1%
(5/62) of O.S.M. had recent infection antibodies (IgM) (Figure 3).
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We validated the questionnaire in this O.S.M. population. A total of 91% (10/11) had
an asymptomatic COVID-19 infection, 9% (1/11) had minor symptoms (chest pain and
dyspnea) that were overlooked by the affected O.S.M. (Table 2), and 27.2% (3/11) reported
being previously in contact with positive COVID-19 patients.
3.2. Application of Paper Surveys for Patients in the Radiotherapy Area
A total of 4,196 surveys answered by 369 patients were obtained from October 2020
to February 2021. We observed that the average oxygen saturation upon entering the
facilities was 96%, and the average temperature was 36.8 ◦ C. We were able to identify five
(1.4%) patients with a maximum value of the cut-off point of the S-Facts patient survey,
which indicates a high probability of presenting the disease. All five patients underwent a
SARS-CoV-2 qRT-PCR confirmation study, and all were positive.
4. Discussion
We tested epidemiological algorithms (R-Track and S-Fact) in the field as a paper and
electronic survey to identify patients and staff in the radiotherapy area, respectively. We
concluded that the sensitivity of the R-Track was 75%, whereas S-Fact was 81.82%. The
difference between the model’s surveys efficiency is likely due to COVID-19 symptoms
adjusted for age and weight in the R-Track model. The sensitivity of R-Track and S-Fact
was slightly higher than Menni et al.’s model, with a sensitivity of 66% and a specificity
of 83% [13]. However, the actual specificity of R-Track and S-Fact could not be calculated
because the confirmatory test (qRT-PCR) was not performed on all 140 oncology staff
members without symptoms.
Another measure that was implemented was the restriction to enter the oncology
center for those accompanying cancer patients. To date, only one companion is allowed to
enter, only if necessary, according to the patient’s conditions.
Data from ASCO (American Society of Clinical Oncology) supports a higher prevalence
of COVID-19 in oncologic patients and a higher risk of death. Especially in leukemia patients
and thyroid cancer (odd risk ratio OR of 12.6 and 3.10 respectively). According to ASCO data,
the rest of the cancers reported an increased range of odds risk ratio of COVID-19 prevalence
(OR of 4.70 to 8.54) and an increased odds risk ratio of death (OR 1.66–3.16) [16–18]. Due to
the high risk that cancer patients represent, it is of great importance to implement prevention
measures. The proposed algorithms represent a low-cost early detection tool.
New SARS-CoV19 variants are reported worldwide. Some of these mutations could
have an impact on the immunological response and, in consequence, on the patient’s
symptoms. These mutations also can change virulence and the pathogenicity of the virus.
For instance, changes in symptomatology could require modifications in the algorithms
and prevent programs from ensuring that new cases are identified. Furthermore, changes
in the disease duration could require changes in the isolation periods will be required.
That is why it is important for the constant evaluation and remodeling of the proposed
algorithm [19].
At the time of writing this article, we compared the prevention actions that we implement in our cancer center and others that have been implemented in cancer centers in
the USA (United States of America). Our prevention measures are very similar to those
implemented in other centers in developed countries, such as the MD Anderson Cancer
Center (MDA) [20], the Memorial Sloan Kettering Cancer Center (MSK) [18], and the DanaFarber Cancer Center (DF) [21]. Among some of the world’s top-ranked oncology centers
(MDA, MSK, and DF), in addition to the international prevention guidelines, each one has
a specific COVID-19 prevention program displayed on their respective website [16,22].
Due to the training that was carried out on 100% of the oncology staff, a total of
14 employees who went on vacation and/or self-reported having COVID-19 symptoms
were not allowed to enter the center. These O.S.M. assisted a COVID hospital, where the
PCR-SARS-CoV-2 test was carried out. The period of disability was of two weeks before
return to work activities. We think that the self-reported by the O.S.M. is attributed to
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the training received, with which we provide them the necessary tools for the correct
identification of suggestive symptoms of COVID-19. This helped us to maintain a low
incidence of infection and thus provide a safe work environment for both employees and
patients. No outbreaks were recorded at the C.U.C.C. from March 2020 to January 2021,
indicating that the use of electronic surveys, P.P.E., early detection, and preventive training
effectively avoided infection outbreaks in our cancer center [23]. Additionally, O.S.M.
increased their sense of safety, even in the worst part of the pandemic, because of the
intense campaign of symptoms information and self-protection, reinforcing the strict use of
the P.P.E. and molecular testing after any suspicious symptoms.
In our study, we observed that dysgeusia/anosmia (82.4%) and meals skipping (76.5%)
are the main algorithm symptoms in COVID-19 positive employees, which corresponds
to the reported literature [13,24]. Other studies found that fatigue and gastrointestinal
manifestations are signs of severe COVID-19 infection [25,26]. We agree that the symptoms
presented during the disease correspond to symptoms of good prognosis, and the symptom
of diarrhea/vomiting and fatigue was presented in six (35.3%) and five (29.4%) individuals,
respectively [27]. None of the employees required hospitalization, for which we conclude
that these symptoms are of a good prognosis. However, to confirm this conclusion, a study
with a higher number of patients would be required.
Applying a paper survey for all patients admitted to the facilities avoided an outbreak
within the radiotherapy area. This approach helped us maintain the patients’ integrity due
to the high likelihood of COVID-19 complications in cancer patients [25].
Only 1.3% of the radiotherapy patients presented an alert of possible infection, which
indicates a low probability of contracting the disease when receiving cancer treatment
within the facilities. We think that using the COVID-19 information pamphlet in cancer
patients was of great help for patients to opportune prevent infection [28].
In this study, we detect SARS-CoV-2 IgM and IgG seroprevalence in 44.3% (n = 62) of O.S.M.
In contrast, Fuereder et al. 2020 reported only 3.2% of seroprevalence in oncology healthcare
professionals (from a population of 62 subjects) [29]. Mahto et al. 2021 [30] described 13% of
the medical staff with IgG antibodies. The lowest seroprevalence reported was 1.8% in staff
members at a French cancer center (from a total of 663) [31]. Published series from Europe in
the first wave of the pandemic reported 5–10% of COVID-19 seroprevalence rates [31,32].
From the 11 asymptomatic O.S.M., three reported close contact with family, friends, or
patients with symptoms or confirmed COVID-19 infection, and of the remaining nine, the
reason for a possible infection is unknown. The incidence of asymptomatic cases reported
in different studies varies widely between 1.6% and >50%, depending on the general testing
rates and the methodology employed. There is consensus that asymptomatic patients can
spread the disease [29,30,32,33]. Additionally, it was demonstrated that asymptomatic
individuals exhibited a weaker immune response and had lower levels of neutralizing
IgG antibodies [34]. Asymptomatic patients presenting low levels of antibodies might be
more likely to become seronegative [35]. Based on these results, we recommend prolonging
public health interventions, including social distancing, hygiene, isolation of high-risk
groups, and widespread testing.
Within the limitations of the study, it is important to mention that we have limited PCR
tests, so we could not perform the PCR on the subjects who were negative for the algorithm.
We could not detect if there were asymptomatic subjects, and we did not were able to
calculate de specificity of the algorithm. Added to this, we consider that it is necessary
to increase the sample size. Moreover, the algorithm does not consider the symptoms
associated with the new variants, the immunity acquired through vaccination, reinfections,
etc. Therefore, it is necessary to adapt the algorithm considering all these factors.
The mobile market in the developing world is considered to be the most rapidly
growing sector [36]. As a perspective, mobile applications and new algorithms will be
necessary as new diseases emerge and genome viruses evolve. Our study represents an
effective and accessible way to solve many issues in the healthcare sector of the developing
world, such as monitoring epidemic diseases as COVID-19. By undertaking these kinds of
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health tools, the progress of these diseases can be delayed or stopped, the financial cost
of the diseases can be reduced, and the quality of patient life can be improved. Although
several countries in developing countries, such as Mexico, have limited resources (for
tests and vaccines). These countries can employ these tools to improve the quality of
healthcare services.
5. Conclusions
The use of epidemiological algorithms, as paper and electronic survey tools, in oncology staff and patients provided a low-cost, safe, and practical way to detect COVID-19 to act
early on isolation and medical treatment. In this way, we reduced outbreaks in the oncology
cancer center. These algorithms applied to oncologic patients are of exceptional value when
early detection, prevention and early intervention, and susceptible patients’ outcomes. The
proposed algorithms could prove to become a suitable detection tool in countries where
qPCR tests and vaccines are insufficient or not available for all the population.
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